In Bid For Genentech, How High Can Roche Go?

Roche's effort to clinch a buy-out of Genentech has moved to a new, critical stage of negotiations. But just how much can Roche afford to pay for the top-of-the-line biotech, which comes with A-list scientific talent, an extensive pipeline heavily weighted in the lucrative arena of oncology, and a price tag to match?